Lung cancer abstracts set to shape discussions at ASCO 2026

OncLive has compiled a preview of lung‑cancer presentations that leading oncologists expect to influence clinical talks at the 2026 ASCO Annual Meeting in Chicago. The preview highlights insights from experts at MD Anderson, Memorial Sloan Kettering and Weill Cornell, who identified the most noteworthy abstracts.

Among the highlighted data is Abstract 8502, which compares lorlatinib with crizotinib as a first‑line option for advanced ALK‑positive disease. The abstract is being watched for its potential impact on treatment sequencing.

The preview also notes that broader oncology topics, such as HR‑positive/HER2‑positive and triple‑negative breast cancer, will feature prominently at the meeting, underscoring the interdisciplinary interest in emerging therapies.

Attendees can use this curated list to prioritize sessions and stay abreast of data that may inform future practice and research directions.